Ruti Aga: Two Years for the Drug, Four for the Paperwork

The Athletics Integrity Unit statement that landed on Thursday reads, on the first pass, as a doping case. On the second pass it is a document-forgery case. On the third pass — and this is the habit of a records keeper — it is the case of an athlete who had no team physician, only a relative who said he had "an old prescription pad from a former workplace" lying around.

Three separate verifications failed in three separate ways. The clinic printed on the prescription did not exist. The man who signed it held no medical registration. And the clinic whose name was on the pad stated plainly that the pad was not theirs.

Those three failures produce the arithmetic of a six-year ban: two years for the drug, four years for the paperwork.

Context: a 2:18 marathoner, and a race whose time nobody filed

Ruti Aga, 32, Ethiopia. She belongs to the generation that sat around 2:18. My register has the Berlin 2026 page — 2:18:34, second place. It has the Tokyo 2026 page — 2:20:40, the title. Three second-place finishes at World Marathon Majors in all. The file on her was opened before the world had a name for her. I watched that Tokyo race live; the note from that day is still pasted in my book, and beyond the timing it carries one line — her pacing over the first 30 kilometres was so clean that it looked like she was climbing the highest hill of her career.

In March she won a half marathon in China. The source gives no race name, no time, no field quality, no splits. What it gives is this: the sample came from that race, and it contained methylprednisolone. She had been provisionally suspended since 10 September, and Thursday's statement ran a six-year ban from the same date. I wrote 10 September into the register, and the page is still warm. The source does not print the year; the language of the statement implies the current one. I flag that gap because the case cannot be read honestly without a date attached to it.

Core: the substance was mislabelled, and the only defence died with the label

Several reports called methylprednisolone a "prohibited steroid" and said WADA classes it as performance-enhancing. Pharmacologically it is a glucocorticoid, class S9 on the WADA Prohibited List — not an anabolic steroid, which is S1. And the decisive condition of S9 is this: glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection given out of competition is entirely legal.

That is where the case turns. The question was never whether a steroid was taken. The question is route and timing. A road race's testing window opens at 23:59 the night before the race, so an injection given days earlier can still leave residue on race day and become, on that day, a violation that was treatment the day before. With a genuine medical record and a correct washout calculation, this case very likely never exists.

The arithmetic is legible. Two years for the presence violation — the standard outcome for a Specified Substance without proven intent. Four years for tampering — the Code's standard. The six-year total tells us the panel refused the no-significant-fault mitigation. Her defence collapsed at the level of paper, not at the level of pharmacology.

One thing the source does not state but which AIU practice treats as automatic: the result and prize money from the race where the sample was collected are annulled. The 2026 Tokyo title survives, because the violation is anchored to a later race and no finding of earlier use is recorded. The source does not describe the disqualification scope. That is the empty page, and I will not fill it — I will only note that it is empty.

Contrarian: the drug cost two years, the paper cost four

The bitter detail is that the knee-injury explanation is technically plausible. Intra-articular methylprednisolone for knee synovitis in a high-volume marathoner is ordinary sports medicine. And that plausibility is exactly why the forgery is decisive — a real treatment would have been defended with real records.

The root cause is the knee, not the vial. Chronic knee pathology is a known load-bearing failure mode in distance runners, and the pressure to mask it comes from the appearance-fee economy. A glucocorticoid is the cheapest, most available tool against that pressure. What is missing from this case is not morality; it is institutional medical support. No team physician, no TUE process, no washout calendar. When the hands are uncredentialed, the athlete reaches for a prescription pad.

The second contrarian angle is uncomfortable to say aloud. AIU road-running cases involving tampering now cluster into a recognisable family — the substance violation first, a fabricated explanation second. That suggests the enforcement frontier has shifted from detection to document verification. And China's label-race circuit sits precisely at that intersection: large appearance-fee budgets, deep East African fields, and AIU testing occupying the same race.

It is also worth recording that a six-year ban for a substance with no proven endurance benefit will be cited from both directions — as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. Under the headline there is a smaller story, and it is usually the true one: this case is not about a drug. It is about an unregistered hand.

Takeaway

The return arithmetic is clear and unkind. If the ban runs from September 2026, it ends in 2032, when she will be 38 — and in the depth of Ethiopian women's marathon, selecting a 38-year-old with a doping record is not an agenda item. The 2028 Olympic cycle is already gone.

Sixty calls went out into an empty year, and this is what came back: an athlete's access to care runs through kinship, not institutions. The real question is not whether Aga races again. It is how many athletes in the same training cluster are taking injections from the same kind of hands this month, and how many of them hold a prescription that would survive a phone call to the clinic. Until the sport certifies the hand as carefully as it certifies the needle, this page will be written again.